✦ LIBER ✦

P85 Direct comparison of primary (neoadjuvant) endocrine therapy vs primary chemotherapy in postmenopausal women with ER-positive breast cancer

✍ Scribed by V. Semiglazov; V. Ivanov; A. Bozhok; A. Kletzel; E. Ziltzova; O. Melnikova; R. Paltuev; G. Dashyan; L. Berstein; N.N. Petrov

Book ID: 114315808
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 145 KB
Volume: 14
Category: Article
ISSN: 0960-9776
DOI: 10.1016/s0960-9776(05)80121-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Primary endocrine therapy vs chemotherap

Primary endocrine therapy vs chemotherapy in postmenopausal ER-positive breast cancer patients

✍ V. Semiglazov; Kletsel; E. Zhiltsova; V. Ivanov; G. Dashyan; A. Bozhok; O. Melni 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 131 KB

0177 Primary endocrine therapy versus ch

0177 Primary endocrine therapy versus chemotherapy in postmenopausal patients with ER-positive breast cancer: 5-year results

✍ V.F. Semiglazov; G.A. Dashyan; V.V. Semiglazov; E.K. Ziltsova; A.A. Malodusheva; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Phase 2 randomized trial of primary endo

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

✍ Vladimir F. Semiglazov; Vladislav V. Semiglazov; Garik A. Dashyan; Elena K. Zilt 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB

## Abstract ## BACKGROUND. Few studies have compared primary neoadjuvant endocrine therapy with neoadjuvant chemotherapy in breast cancer patients. The need for preoperative chemotherapy with doxorubicin or taxanes may be reduced in postmenopausal patients with estrogen receptor (ER)‐positive and/

Risk for second primary non-breast cance

Risk for second primary non-breast cancer in pre- and postmenopausal women with breast cancer not treated with chemotherapy, radiotherapy or endocrine therapy

✍ Rikke Langballe; Jørgen H. Olsen; Michael Andersson; Lene Mellemkjær 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 162 KB

277 POSTER Breast-conserving surgery (BC

277 POSTER Breast-conserving surgery (BCS) following neoadjuvant endocrine therapy: exemestane (E) vs tamoxifene (T) in postmenopausal (PM) women with ER-positive breast cancer (T2N1, T3NO-1, T4NOMO)

✍ V. Semiglazov; E. Zhiltzova; V.V. Semiglazov; A. Kletsel; V. Ivanov; A. Bozhok; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 60 KB

0161 Letrozole vs. tamoxifen as adjuvant

0161 Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Update of the BIG 1-98 primary core analysis

✍ B. Thürlimann 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 53 KB